Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH
Top

30-05-2014 | Gout | Book Chapter | Article

4. Treatment of Hyperuricemia in Gout

Authors: Fernando Pérez-Ruiz, Ana Maria Herrero-Beites

Authors: Fernando Perez-Ruiz, Ana Maria Herrero-Beites

Publisher: Springer Healthcare Ltd.

Login to get access

Abstract

The treatment of gout with chronic clinical manifestations comprises three aspects, in the following order of clinical importance: (1) reducing serum urate to the therapeutic range to dissolve monosodium urate crystals (MSUCs) formed in tissues, using urate-lowering therapy (ULT); (2) preventing or reducing the risk of episodes of acute inflammation (EAIs) that appear and even increase in frequency during the initiation of ULT (prophylaxis); (3) promptly, safely, and effectively treating any EAIs that may appear until proper and stable serum urate levels are achieved.

Literature
1. Perez-Ruiz F. Treating to target: an strategy to cure gout. Rheumatology (Oxford). 2009; 48(suppl 2):ii9-ii14.
2. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II. Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006; 65:1312-1324.
3. Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012; 64:1431-1446.
4. Perez-Ruiz F, Schlesinger N. Management of gout. Scand J Rheumatol. 2008;37:81- 89.
5. Perez-Ruiz F, Lioté F. Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout? Arthritis Rheum. 2007; 57:1324-1328.
6. Stamp LK, Zhu X, Dalbeth N, Jordan S, Edwards NL, Taylor W. Serum urate as a soluble biomarker in chronic gout—evidence that serum urate fulfills the OMERACT validation criteria for soluble biomarkers. Semin Arthritis Rheum. 2011; 40:483-500.
7. Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum. 2002; 47:356-360.
8. Perez-Ruiz F, Martin I, Canteli B. Ultrasonographic measurement of tophi as an outcome measure for chronic gout. J Rheumatol. 2007; 34:1888-1893.
9. Perez-Ruiz F, Herrero-Beites AM, Carmona L. A two-stage approach to the treatment of hyperuricemia in gout: the “dirty dish” hypothesis. Arthritis Rheum. 2011; 63:4002-4006.
10. Choi HK. Dietary risk factors for rheumatic diseases. Curr Opin Rheumatol. 2005; 17:141-146.
11. U.S. Department of Agriculture and U.S. Department of Health and Human Services. Dietary Guidelines for Americans, 2010. 7th Edition. Washington, DC: U.S. Government Printing Office; 2010. http://​www.​health.​gov/​dietaryguideline​s/​dga2010/​dietaryguideline​s2010.​pdf. Accessed May 16, 2013.
12. Perez Ruiz F, Herrero-Beites AM. Evaluation and treatment of gout as a chronic disease. Adv Ther. 2012;29:935-946.
13. Jansen TL, Richette P, Perez-Ruiz F, et al. International position paper on febuxostat. Clin Rheumatol. 2010;29:835-840.
14. Annemans L, Spaepen E, Gaskin M, et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis. 2008; 67: 960-966.
15. Perez-Ruiz F, Carmona L, Yebeñes MJG, et al; on behalf of the GEMA Study Group, Sociedad Espanola de Reumatologia. An audit of the variability of diagnosis and management of gout in the rheumatology setting: the Gout Evaluation and Management study. J Clin Rheumatol. 2011; 17:349-355.
16. Reinders MK, Haagsma C, Jansen TLThA, et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300–600 mg/day versus benzbromarone 100–200 mg/day in patients with gout. Ann Rheum Dis. 2009; 68:892-897.
17. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984; 76:47-56.
18. Dalbeth N, Kumar S, Stamp L, Gow P. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol. 2006; 33:1646-1650.
19. Perez-Ruiz F, Hernando I, Villar I, Nolla JM. Correction of allopurinol dosing should be based on clearance of creatinine, but not plasma creatinine levels: another insight to allopurinol-related toxicity. J Clin Rheumatol. 2005; 11:129-133.
20. Stamp LK, Taylor WJ, Jones PB, et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum. 2012; 64:2529-2536.
21. Rundles RW, Metz EN, Silberman HR. Allopurinol in the treatment of gout. Ann Intern Med. 1966; 64:229-268.
22. Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008; 128:35-44.
23. Cacoub P, Musette P, Descamps V, et al. The DRESS syndrome: a literature review. Am J Med. 2011; 124:588-597.
24. Lonjou C, Borot N, Sekula P, et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics. 2008; 18:99-107.
25. Khosravan R, Grabowski BA, Wu JT, Joseph-Ridge N, Vernillet L. Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects. Clin Pharmacokinet. 2006; 45:821-841.
26. Perez-Ruiz F, Dalbeth N, Schlesinger N. Febuxostat, a novel drug for the treatment of hyperuricemia of gout. Future Rheumatol. 2008; 3:421-427.
27. Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005; 353:2450-2461.
28. Becker MA, Schumacher HR, Espinoza LR, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CON FIRMS trial. Arthritis Res Ther. 2010; 12:R63.
29. Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009; 36:1282.
30. Schumacher HR Jr, Becker MA, Lloyd E, MacDonald PA, Lademacher C. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford). 2009; 48:188-194.
31. Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, Herrero-Beites A, Garcia-Erauskin G, Ruiz-Lucea E. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis. 1998; 57:545-549.
32. Perez-Ruiz F, Calabozo M, Fernandez-Lopez MJ, et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. J Clin Rheumatol. 1999; 5:49-55.
33. Perez-Ruiz F, Gomez-Ullate P, Amenabar JJ, et al. Long-term efficacy of hyperuricaemia treatment in renal transplant patients. Nephrol Dial Transplant. 2003;18:603-606.
34. Pui K, Gow PJ, Dalbeth N. Efficacy and tolerability of probenecid as urate-lowering therapy in gout; clinical experience in high-prevalence. J Rheumatol. 2013; 40:872-876.
35. Sundy JS, Hershfield MS. Uricase and other novel agents for the management of patients with treatment-failure gout. Curr Rheum Rep. 2007; 9:258-264.
36. Edwards NL. Treatment-failure gout: a moving target. Arthritis Rheum. 2008; 58:2587-2590.
37. Sherman MR, Saifer MGP, Perez-Ruiz F. PEG-uricase in the management of treatment-resistant gout and hyperuricemia. Adv Drug Deliv Rev. 2008; 60:59-68.
38. European Medicines Agency Web site. Krystexxa Summary of Product Characteristics. http://​www.​ema.​europa.​eu/​docs/​en_​GB/​document_​library/​EPAR_​-_​Product_​Information/​human/​002208/​WC500138318.​pdf. Accessed May 16, 2013.
39. Sundy JS, Baraf HSB, Yood RA, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011; 306:711-720.
40. Perez-Ruiz F. New treatments for gout. Bone Joint Spine. 2007; 74:313-315.
Image Credits